IP Library Granted Patent US 8,519,133
Granted Patent B2
US 8,519,133 · App. 12/797,642 · Granted Aug 27, 2013

Preparation of 6-alpha-amino N-substituted morphinans by catalytic hydrogen transfer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,519,133
App. No.
12/797,642
Granted
Aug 27, 2013
Kind
B2
Abstract

The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer.

Claims (39)

1. A process for preparing a 6-alpha-amino N-substituted morphinan, the process comprising contacting a 6-keto N-substituted morphinan with an amine source, a hydrogen donor comprising a formate ion, a transition metal catalyst, and a proton acceptor to form the 6-alpha-amino N-substituted morphinan, wherein the amine source comprises the formula R 6 NH 2 , wherein R 6 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

2. The process of claim 1 , wherein the 6-keto N-substituted morphinan is selected from the group consisting of hydrocodone, hydromorphone, oxycodone, oxymorphone, naloxone, and naltrexone; the amine source is selected from the group consisting of a primary amine and an ammonium salt; the hydrogen donor comprising a formate ion is selected from the group consisting of formic acid, a salt of formic acid, and a mixture of formic acid and an organic base; the transition metal catalyst comprises ruthenium, rhodium, or iridium; and the proton acceptor has a pKa of great than about 9.

3. The process of claim 1 , wherein contact between the 6-keto N-substituted morphinan, the amine source, the hydrogen donor, and the transition metal catalyst forms a first intermediate comprising a formate salt of a 6-imine N-substituted morphinan, the first intermediate being converted in situ to a second intermediate comprising a formate salt of a 6-alpha-amino morphinan, and contact between the second intermediate and the proton acceptor forms the 6-alpha-amino N-substituted morphinan.

4. The process of claim 1 , wherein the process produces a product comprising the 6-alpha-amino N-substituted morphinan and no more than about 2% of a 6-beta-amino morphinan epimer.

5. A process for preparing a compound of Formula (IV):

the process comprising:

reducing a compound of Formula (I) in the presence of an amine source (R 6 NH 2 ), a hydrogen donor comprising a formate ion, a transition metal catalyst, and a proton acceptor to form the compound of Formula (IV), the compound of Formula (I) having the structure:

wherein:

R is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 1 and R 2 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 15 ;

R 3 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 15 ;

R 6 is selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 14 is selected from the group consisting of hydrogen and {—}OR 15 ; and

R 15 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxy protecting group.

6. The process of claim 5 , wherein R 1 , R 2 , R 7 , and R 8 are hydrogen; R 14 is hydrogen or hydroxyl; R is selected from the group consisting of alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, aryl, and heterocyclo; R 3 is selected from the group consisting of alkoxy, hydroxy, and protected hydroxyl; the hydrogen donor comprising a formate ion is selected from the group consisting of formic acid, a salt of formic acid, and a mixture of formic acid and an organic base; R 6 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, and aryl, and the amine source is a primary amine; the molar ratio of the compound of Formula (I) to the primary amine to the hydrogen donor is from about 1:1:1 to about 1:5:20; the transition metal catalyst comprises ruthenium, rhodium, or iridium; the molar ratio of the compound of Formula (I) to the transition metal catalyst is about 1:0.0001 to about 1:0.01; the reaction between the compound of Formula (I), the amine source, the transition metal catalyst, and the hydrogen donor occurs in the presence of a solvent selected from the group consisting of an aprotic solvent, a protic solvent, a non-polar solvent, and combinations thereof; the reaction between the compound of Formula (I), the amine source, the transition metal catalyst, and the hydrogen donor occurs at a temperature from about 20° C. to about 100° C.; and the proton acceptor has a pKa of greater than about 9 and is selected from the group consisting of ammonia, ammonium hydroxide, potassium hydroxide, and sodium hydroxide.

7. The process of claim 5 , wherein R 6 is hydrogen and the amine source is an ammonium salt.

8. The process of claim 7 , wherein the molar ratio of the compound of Formula (I) to the ammonium salt to the hydrogen donor is from about 1:2:1 to about 1:20:20.

9. The process of claim 5 , wherein the hydrogen donor comprises formic acid and triethylamine.

10. The process of claim 9 , wherein the molar ratio of the compound of Formula (I) to triethylamine is from about 1:1 to about 1:10.

11. The process of claim 5 , wherein the transition metal catalyst is selected from the group consisting of dichloro(arene)Ru(II) dimer, dichloro(pentamethylcyclopentadienyl)Rh(II) dimer, BINAP-Ru(II) diacetate, BINAP-Ru(II) dichloride, BINAP-Ru(II) dibromide, BINAP-Ru(II) diiodide, [RuCl((R or S)BINAP)(C 6 H 6 )]Cl, dichloro(pentamethylcyclopentadienyl)iridium(III) dimer, Ru(III)chloride, RuCl 3 hydrate, Ru(III) acetylacetonate, tetraalkylammonium RuCl 4 , and pyridinium RuCl 4 .

12. The process of claim 5 , wherein the transition metal catalyst is a Noyori catalyst.

13. The process of claim 5 , wherein a first intermediate comprising Formula (II) is formed after the compound of Formula (I) is contacted with the amine source, the hydrogen source, and the transition metal catalyst, and the first intermediate is converted in situ to a second intermediate comprising Formula (III):

wherein:

R is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 1 and R 2 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 15 ;

R 3 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 15 ;

R 6 is selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 14 is selected from the group consisting of hydrogen and {—}OR 15 ; and

R 15 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxy protecting group.

14. The process of claim 5 , wherein the compound of Formula (IV) has a structure of Formula (V):

wherein:

R is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 1 and R 2 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 15 ;

R 3 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 15 ;

R 14 is selected from the group consisting of hydrogen and {—}OR 15 ; and

R 15 is selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxy protecting group.

15. The process of claim 5 , wherein the amine source is a primary amine; the molar ratio of the compound of Formula (I) to the primary amine is about 1:2; the hydrogen donor comprises formic acid and triethylamine; the molar ratio of the compound of Formula (I) to formic acid to triethylamine is about 1:12:3; the transition metal catalyst is dichloro(p-cymene)Ru(II) dimer; the molar ratio of the compound of Formula (I) to the Ru(II) dimer is from about 1:0.001 to 1:0.01; reaction with the primary amine, Ru(II) dimer, and formic acid/triethylamine occurs in the presence of acetonitrile and at a temperature from about 20° C. to about 60° C.; the proton acceptor is ammonia; and reaction with the proton acceptor occurs in a protic solvent system comprising water, at a pH of about 9.5, and at room temperature.

16. The process of claim 5 , wherein the amine source is ammonium acetate; the molar ratio of the compound of Formula (I) to ammonium acetate is about 1:12; the hydrogen donor comprises formic acid and triethylamine; the molar ratio of the compound of Formula (I) to formic acid to triethylamine is about 1:12:5; the transition metal catalyst is dichloro(p-cymene)Ru(II) dimer; the molar ratio of the compound of Formula (I) to the Ru(II) dimer is from about 1:0.001 to 1:0.01; reaction of the ammonium acetate, the Ru(II) dimer, and the formic acid/triethylamine occurs in the presence of ethanol and at a temperature from about 20° C. to about 60° C.; the proton acceptor is ammonia; and reaction with the proton acceptor occurs in a protic solvent system comprising water, at a pH of about 9.5, and at room temperature.

17. The process of claim 5 , wherein the optical activity of the compounds of Formulas (I) or (IV) is (−) or (+), the configuration of C-5, C-13, C-14, and C-9, respectively, is selected from the group consisting of RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, and SSSS, provided that C-15 and C-16 are both either on the alpha face or the beta face of the molecule; and the process produces a product comprising the compound of Formula (IV) and less than 2% of a 6.beta-amino epimer.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →